SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 31st, 2020 • Vaccinex, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 31st, 2020 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of July 30, 2020, between Vaccinex, Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) and 3i, LP, as collateral agent (in such capacity, the “Collateral Agent”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 31st, 2020 • Vaccinex, Inc. • Pharmaceutical preparations
Contract Type FiledJuly 31st, 2020 Company IndustryThis Registration Rights Agreement (this “Agreement”) is made and entered into as of July 31, 2020, between Vaccinex, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
7% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE DUE AUGUST 3, 2021Convertible Security Agreement • July 31st, 2020 • Vaccinex, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 31st, 2020 Company Industry JurisdictionTHIS 7% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 7% Original Issue Discount Senior Secured Convertible Debentures of Vaccinex, Inc., a Delaware corporation (the “Company”), having its principal place of business at 1895 Mount Hope Avenue, Rochester, New York 14620, designated as its 7% Original Issue Discount Senior Secured Convertible Debenture due August 3, 2021 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
SECURITY AGREEMENTSecurity Agreement • July 31st, 2020 • Vaccinex, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 31st, 2020 Company Industry JurisdictionThis SECURITY AGREEMENT, dated as of July 31, 2020 (this “Agreement”), is among Vaccinex, Inc., a Delaware corporation (the “Company”), each Additional Debtor from time to time party hereto (together with the Company, the “Debtors”) and 3i, LP, as collateral agent (in such capacity, the “Collateral Agent”) for the holders of the Company’s 7% Original Issue Discount Senior Secured Convertible Debentures due August 3, 2021, in the original aggregate principal amount of $8,640,000 (collectively, as amended, restated or otherwise modified from time to time, the “Debentures”), their endorsees, transferees and assigns (collectively, the “Secured Parties”).